Recursive partitioning as an approach to selection of immune markers for tumor diagnosis.

PURPOSE AND EXPERIMENTAL DESIGN Cancer sera contain antibodies which react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs), but the low frequency of positive reactions against any individual antigen has precluded use of autoantibodies as useful diagnostic markers. With enzyme immunoassay, we examined antibody frequencies to a panel of seven TAAs, c-myc, cyclin B1, IMP1, Koc, p53, p62, and survivin, in 527 cancer patients (64 breast cancer patients, 45 colorectal cancers, 91 gastric cancers, 65 hepatocellular carcinomas, 56 lung cancers, and 206 prostate cancers), and 346 normals. We used recursive partitioning to assess whether we could accurately classify individuals as either cancer patients or normals on the basis of the profile of antibody reactivity to the seven TAAs for each individual. RESULTS Recursive partitioning resulted in the selection of subsets of the seven-panel TAA, which differentiated between tumors and controls, and these subsets were unique to each cancer cohort. The classification trees had sensitivities ranging from 0.77 to 0.92 and specificities ranging from 0.85 to 0.91 in the cancer cohorts when normal means +2 SDs were used as standard cutoffs for immunoassay positivity. Antibody to cyclin B1 was the initial discriminating node for gastric and lung cancers, and for hepatocellular carcinoma, and was a subsequent discriminating node in all of the other cancer cohorts. c-myc was the initial discriminating node in breast cancer, p62 in prostate cancer, and IMP1 in colon cancer. Recursive partitioning demonstrated that no more than three of the seven TAAs were needed for any cancer cohort to arrive at these levels of sensitivity and specificity. CONCLUSIONS This initial study shows that multiple antigen miniarrays can provide accurate and valuable tools for cancer detection and diagnosis. Performance of the miniarrays might be enhanced by other combinations of TAAs appropriately selected for different cancer cohorts.

[1]  Thomas K. Hoffmann,et al.  Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells , 2001, The Journal of experimental medicine.

[2]  R. Reed.  Clinical Epidemiology: A Basic Science for Clinical Medicine. Second edition , 1992, The Journal of the American Board of Family Medicine.

[3]  H. Friess,et al.  Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein , 1997, Oncogene.

[4]  K R Hess,et al.  Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  F. Nielsen,et al.  A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development , 1999, Molecular and Cellular Biology.

[6]  J A Koziol,et al.  Statistical approach to immunosuppression classification using lymphocyte surface markers and functional assays. , 1983, Cancer research.

[7]  Xuan Peng,et al.  A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma , 1999, The Journal of experimental medicine.

[8]  J. Bartek,et al.  Are all cancer genes equal? , 2001, Nature.

[9]  J. Cooper,et al.  Validation of the RTOG recursive partitioning classification for head and neck tumors , 2001, Head & neck.

[10]  S. Reed,et al.  Immune response to cyclin B1 in hepatocellular carcinoma , 1997, Hepatology.

[11]  A. Hanlon,et al.  Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[13]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[14]  L. Meisner,et al.  Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein. , 2000, Cancer research.

[15]  W. Sause,et al.  Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. , 2000, International journal of radiation oncology, biology, physics.

[16]  William N. Venables,et al.  Modern Applied Statistics with S-Plus. , 1996 .

[17]  Heping Zhang,et al.  Cell and tumor classification using gene expression data: Construction of forests , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[19]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[20]  S. Singletary,et al.  Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation. , 2001, International journal of radiation oncology, biology, physics.

[21]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[22]  M. Province,et al.  19 Classification methods for confronting heterogeneity , 2001 .

[23]  D. Sackett,et al.  The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.

[24]  Burton H. Singer,et al.  Recursive partitioning in the health sciences , 1999 .

[25]  E. Tan.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. , 2001, The Journal of clinical investigation.

[26]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[27]  E. Rieber,et al.  Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. , 2000, Cancer research.

[28]  E. Chan,et al.  Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. , 2001, Clinical immunology.

[29]  E. Rieber,et al.  Advances in Brief Antibody Response to the Tumor-associated Inhibitor of Apoptosis Protein Survivin in Cancer Patients 1 , 2000 .

[30]  J. Koziol,et al.  Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[32]  M. Xiong,et al.  Recursive partitioning for tumor classification with gene expression microarray data , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Province,et al.  Classification methods for confronting heterogeneity. , 2001, Advances in genetics.